Details

Autor(en) / Beteiligte

• Miller, Merlene
• Chen, Amanda LC
• Stokes, Stan D.
• Silverman, Susan
• Bowirrat, Abdalla
• Manka, Matthew
• Manka, Debra
• Miller, David K.
• Perrine, Kenneth
• Chen, Thomas JH
• Bailey, John A.
• Downs, William
• Waite, Roger L.
• Madigan, Margaret A.
• Braverman, Eric R.
• Damle, Uma
• Kerner, Mallory
• Giordano, John
• Morse, Siobhan
• Oscar-Berman, Marlene
• Barh, Debmalya
• Blum, Kenneth

Titel

Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study

Ist Teil von

• Journal of psychoactive drugs, 2012-11, Vol.44 (5), p.398-409

Ort / Verlag

United States: Taylor & Francis Group

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Substance use disorders (SUD) are inheritable and the culprit is hypodopaminergic function regulated by reward genes. We evaluated a natural dopaminergic agonist; KB220 intravenous (IV) and oral variants, to improve dopaminergic function in SUD. Our pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale. The combined group (IV and oral) did significantly better than the oral-only group over the first week and 30-day follow-up period. Next, the combination was given to129 subjects and three factors; Emotion, Somatic, and Impaired Cognition, with eigenvalues greater than one were extracted for baseline CASS-Revised (CASS-R) variables. Paired sample t-tests for pre and post-treatment scales showed significant declines (p = .00001) from pre- to post-treatment: t = 19.1 for Emotion, t = 16.1 for Somatic, and t = 14.9 for Impaired Cognition. In a two-year follow-up of 23 subjects who underwent KB220IV therapy (at least five IV treatments over seven days) plus orals for 30+ days: 21 (91%) were sober at six months, 19 (82%) having no relapse; 19 (82%) were sober at one year, 18 (78%) having no relapse; and 21 (91%) were sober two-years post-treatment, 16 (70%) having no relapse. We await additional research and advise caution in interpreting these encouraging results.